Moody Aldrich Partners LLC Has $948,000 Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Moody Aldrich Partners LLC reduced its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 1.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 48,961 shares of the biotechnology company’s stock after selling 918 shares during the quarter. Moody Aldrich Partners LLC’s holdings in Arrowhead Pharmaceuticals were worth $948,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Avoro Capital Advisors LLC raised its stake in Arrowhead Pharmaceuticals by 657.1% during the first quarter. Avoro Capital Advisors LLC now owns 8,555,555 shares of the biotechnology company’s stock worth $244,689,000 after acquiring an additional 7,425,555 shares in the last quarter. Vanguard Group Inc. increased its position in Arrowhead Pharmaceuticals by 16.2% during the 1st quarter. Vanguard Group Inc. now owns 12,404,050 shares of the biotechnology company’s stock worth $354,756,000 after purchasing an additional 1,731,974 shares in the last quarter. Squarepoint Ops LLC acquired a new position in Arrowhead Pharmaceuticals during the 2nd quarter worth approximately $9,976,000. Natixis bought a new position in Arrowhead Pharmaceuticals in the 1st quarter valued at approximately $5,834,000. Finally, Millennium Management LLC boosted its position in Arrowhead Pharmaceuticals by 61.9% in the second quarter. Millennium Management LLC now owns 529,251 shares of the biotechnology company’s stock valued at $13,755,000 after buying an additional 202,280 shares in the last quarter. Institutional investors and hedge funds own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Stock Up 1.8 %

NASDAQ ARWR traded up $0.35 on Thursday, reaching $20.27. The company had a trading volume of 112,057 shares, compared to its average volume of 1,210,343. The company’s fifty day moving average is $21.20 and its 200 day moving average is $23.80. The stock has a market capitalization of $2.52 billion, a P/E ratio of -4.69 and a beta of 0.95. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $17.05 and a 52-week high of $39.83.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.80). The business’s quarterly revenue was down 100.0% on a year-over-year basis. During the same period last year, the company earned ($0.96) EPS. On average, research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -4.31 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have commented on ARWR shares. Chardan Capital reiterated a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, July 17th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research report on Monday, September 9th. Piper Sandler reiterated an “overweight” rating and set a $62.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, October 8th. Royal Bank of Canada reiterated an “outperform” rating and issued a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Thursday, September 26th. Finally, B. Riley reiterated a “buy” rating and set a $55.00 price target on shares of Arrowhead Pharmaceuticals in a report on Monday, August 12th. One analyst has rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $45.33.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.